Skip to main content

Table 1 Summary characteristics of CQ-treated patients

From: Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy)

 

Cases*

Controls

p-value (two-sided t-test)

Number of Individuals

24

13

-

Mean Age (S.D.) [years]

61.18 (10.45)

49.11 (9.74)

0.0016

Treatment Duration (S.D.) [months]

153.1 (97.77)

121.8 (58.74)

0.2327

Daily dose per body weight (S.D.) [mg/kg]

4.00 (1.26)

3.90 (0.84)

0.7966

Daily dose per ideal weight (S.D.) [mg/kg]

4.90 (1.25)

4.07 (0.31)

0.0078

Fraction of Individuals > 60 years

0.71

0.15

-

Male [%]

0.04

0.23

0.1622

  1. *Patients treated with CQ and affected with toxic maculopathy.
  2. Patients treated with CQ and no signs of toxic maculopathy.